Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01315
|
|||||
| Drug Name |
Voxilaprevir
|
|||||
| Synonyms |
0570F37359; DB12026; GS-9857; J3.665.048F; SCHEMBL15412621; UNII-0570F37359; Voxilaprevir; Voxilaprevir (USAN/INN); Voxilaprevir [USAN:INN]
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Hepatitis C virus infection [ICD11: 1E50.2, 1E51.1] | Phase 1 | [1] | |||
| Therapeutic Class |
Antiviral Agent
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C40H52F4N6O9S
|
|||||
| Canonical SMILES |
CCC1C2CN(C1C(=O)NC3(CC3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)C(NC(=O)OC5CC5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C
|
|||||
| InChI |
InChI=1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1
|
|||||
| InChIKey |
MZBLZLWXUBZHSL-FZNJKFJKSA-N
|
|||||
| CAS Number |
CAS 1535212-07-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 868.9 | Topological Polar Surface Area | 204 | ||
| Heavy Atom Count | 60 | Rotatable Bond Count | 9 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 15 | |||
| XLogP |
5.9
|
|||||
| PubChem CID | ||||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT02402452) Pharmacokinetics of GS-9857 in Adults With Normal Renal Function and Severe Renal Impairment | |||||
| 2 | Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.